Equillium (EQ) Revenue (2023 - 2024)
Equillium (EQ) reported Revenue of $4.4 million for Q4 2024, down 52.32% year-over-year from $9.2 million in Q1 2024, and down 63.88% on a QoQ basis from $12.2 million in Q3 2024.
Equillium (EQ) has 2 years of Revenue data on file, last reported at $4.4 million in Q4 2024.
- Quarterly Revenue fell 52.32% year-over-year to $4.4 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $4.4 million (down 90.43% YoY) and the FY2024 annual result came in at $41.1 million, up 13.89% from the prior year.
- Revenue retreated to $4.4 million in Q4 2024 per EQ's latest filing, from $12.2 million in the prior quarter.
- Across five years, Revenue topped out at $13.9 million in Q2 2024 and bottomed at $4.4 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Equillium | 279.21 Mn | 218.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4.39 Mn |
| Sep 30, 2024 | 12.16 Mn |
| Jun 30, 2024 | 13.85 Mn |
| Mar 31, 2024 | 10.69 Mn |
| Dec 31, 2023 | 9.21 Mn |
| Sep 30, 2023 | 8.87 Mn |
| Jun 30, 2023 | 9.12 Mn |
| Mar 31, 2023 | 8.88 Mn |